pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 8·1 min read
save

AI licensure debate overlooks physician responsibility for patient outcomes

Jul 8, 2026·read at STAT ↗Neutral

The authors argue that discussions about licensing artificial intelligence tools in medicine miss the core purpose of licensure, which is accountability for clinical results. They illustrate a scenario where a cardiologist overrides an algorithm’s diagnosis and the patient recovers, highlighting that the physician, not the software creator, bears the legal risk.

If the physician had accepted the algorithm and the patient was harmed, the doctor’s license would be at stake, while the engineers and vendors would face little direct liability. This underscores that licensure has always been about responsibility, not merely passing an exam.

The piece calls for a shift in focus toward defining who is answerable when AI influences treatment decisions, rather than simply setting testing standards for AI systems.

The authors, both involved in medical AI governance, suggest that future regulatory frameworks should reflect the human element of clinical judgment and the ultimate accountability of licensed practitioners.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: The AI licensure debate is missing the point of licensure”

read at STAT ↗
1,124 words · retrieved Jul 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING
topics
Cardiology4AdCom2Alzheimer's DiseasePeptide Therapeutic

related stories

  • 20h agoNovartis may cut around 130 in Switzerland while relocating biologics productionBioSpace
  • Jun 1The hidden history of BPC-157, a favorite MAHA peptideSTAT
  • May 6Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?STAT
  • Aug 28STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugsSTAT
  • Aug 27RFK Jr. said a Samoa trip had nothing to do with vaccines. New documents refute thatSTAT